10-K: Cardinal Health Posts Strong Earnings Amid Strategic Shift

Cardinal Health reports significant earnings growth in fiscal 2025, driven by strategic acquisitions and specialty pharmaceutical sales, despite a revenue dip from contract expirations.

Summary

• Revenue decreased 2% to $222.6 billion for fiscal 2025, primarily due to the expiration of OptumRx contracts, partially offset by growth in branded and specialty pharmaceutical sales.
• GAAP operating earnings surged 83% to $2.275 billion, benefiting from increased contributions from branded and specialty pharmaceutical products, MSO platform acquisitions, and favorable comparison to prior year's goodwill impairment charges.
• Non-GAAP operating earnings increased 15% to $2.786 billion.
• GAAP diluted EPS rose 87% to $6.45, and non-GAAP diluted EPS increased 9% to $8.24.
• Cash and equivalents stood at $3.9 billion at June 30, 2025, down from $5.1 billion in the prior year.
• Net cash provided by operating activities was $2.4 billion, impacted by the unwinding of negative net working capital from OptumRx contracts and $798 million in opioid litigation payments.
• The company deployed $5.3 billion for acquisitions in fiscal 2025, including Advanced Diabetes Supply Group (ADS) for $1.1 billion, a 73% stake in GI Alliance (GIA) for approximately $2.8 billion, Urology America for $360 million, and Integrated Oncology Network (ION) for $1.1 billion.
• New long-term debt of $2.9 billion was issued in November 2024, and an $800 million term loan was borrowed in April 2025 to fund acquisitions and for general purposes.
• Share repurchases totaled $765 million in fiscal 2025, with $2.7 billion remaining under existing authorization.
• Quarterly dividends increased 1% to $2.02 per share for fiscal 2025, with a further increase to $0.5107 per share approved for July 2025 payment.

Sentiment

Score: 8

Explanation: The filing indicates strong strategic execution with significant acquisitions driving earnings growth, effective capital deployment through dividends and share repurchases, and proactive management of known challenges like the OptumRx contract expiration. While revenue declined, the underlying profitability and strategic positioning appear robust, suggesting a positive outlook despite ongoing legal and regulatory complexities.

Positives

• Significant increase in GAAP operating earnings (83%) and non-GAAP operating earnings (15%) year-over-year.
• Strong growth in GAAP diluted EPS (87%) and non-GAAP diluted EPS (9%).
• Successful execution of strategic acquisitions in high-growth areas like MSO platforms (GI Alliance, ION, Urology America) and at-Home Solutions (ADS), enhancing segment profit.
• Increased contribution from branded and specialty pharmaceutical products and BioPharma Solutions.
• Positive impact from the Pharma segment generics program, excluding OptumRx contract expiration.
• Volume growth from existing customers in the GMPD segment and beneficial impact of cost optimization initiatives.
• Growth across all 'Other' operating segments: at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics.
• Continued return of capital to shareholders through increased dividends and substantial share repurchases ($765 million in fiscal 2025).
• Net recoveries of $171 million in class action antitrust litigation in fiscal 2025.

Negatives

• Overall revenue decreased 2% due to the expiration of the OptumRx contracts, which accounted for 17% of consolidated revenue in fiscal 2024.
• Cash and equivalents decreased to $3.9 billion from $5.1 billion, reflecting significant cash deployment for acquisitions.
• Net cash provided by operating activities decreased to $2.4 billion from $3.8 billion, impacted by the unwinding of negative net working capital from OptumRx and opioid litigation payments.
• Increased interest expense to $215 million from $51 million due to new debt financing.
• Increased SG&A expenses by 8% to $5.4 billion, primarily due to acquisitions and higher costs to support sales growth.
• Increased amortization and other acquisition-related costs to $464 million from $284 million.
• Acquisition-related cash and share-based compensation costs of $126 million in fiscal 2025.

Risks

• Rigorous and evolving regulatory and licensing requirements, including potential non-compliance leading to sanctions, recalls, or product liability claims.
• Ongoing investigations and lawsuits related to healthcare fraud and abuse laws, including a Civil Investigative Demand from the Department of Justice regarding potential Anti-Kickback Statute and False Claims Act violations.
• Product quality issues, such as the FDA warning letter concerning plastic syringes sourced from a third-party Chinese manufacturer, could lead to supply disruptions, increased costs, or regulatory actions.
• Adverse changes in tax laws or challenges to tax positions, including the impact of the One Big Beautiful Bill Act (OBBBA) and ongoing IRS audits related to prior tax benefits.
• Uncertainties and potential adverse impacts from changes in the U.S. healthcare environment, including Medicare/Medicaid reimbursement levels, drug pricing regulations, and the 340B drug pricing program.
• Significant accrued liabilities ($4.9 billion) and ongoing payments related to opioid litigation settlements, with potential for unforeseen costs or penalties if compliance is not maintained.
• Unpredictable outcomes and potential adverse impacts on cash flows or results from other legal proceedings, including IVC filter product liability lawsuits.
• Exposure to economic, political, and currency risks from global operations, including tariffs and trade restrictions (e.g., Uyghur Forced Labor Prevention Act) that could increase costs or disrupt supply.
• Volatility in commodity prices (e.g., oil-based resins, latex) and dependence on sole suppliers, which could lead to increased costs or supply interruptions.
• Intense competitive pressures across all segments, potentially affecting margins if cost reductions or new service offerings cannot offset pricing pressures.
• Dependence on the proper functioning and security of information systems and distribution networks, with risks from cyber-attacks, ransomware, and AI-powered threats, potentially leading to financial losses or operational disruptions.
• Significant sales and credit concentration with key customers, particularly CVS Health (30% of fiscal 2025 revenue), posing a risk if relationships change or payments default.
• Risks associated with integrating and managing recent and future acquisitions, including diversion of management attention, retention of key personnel, system integration challenges, unforeseen liabilities, and regulatory changes limiting MSO ownership.
• Potential for future goodwill or other long-lived asset impairments if reporting units fail to meet financial plans or if key assumptions change.
• Impacts from events outside of control, such as public health crises, extreme weather, and geopolitical events, which can disrupt operations and supply chains.

Future Outlook

The company expects capital expenditures in fiscal 2026 to be approximately $600 million, primarily for manufacturing and distribution infrastructure projects and technology investments. It anticipates combining at-Home Solutions and ADS into a single reporting unit in the future. The company also announced a definitive agreement to acquire Solaris Health, a urology MSO, for approximately $1.9 billion in cash, with an estimated $500 million in GIA common units to be issued, subject to customary closing conditions and regulatory approvals. The majority of remaining opioid litigation payments are expected through 2038. The impact of the recently signed OBBBA tax reform on consolidated financial statements is currently being evaluated.

Management Comments

• "We currently believe that, based on available capital resources and projected operating cash flow, we have adequate capital resources to fund our operations and expected future cash needs."
• "If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing."
• "We expect capital expenditures in fiscal 2026 to be approximately $600 million and primarily related to manufacturing and distribution infrastructure projects and technology investments."
• "We intend to vigorously defend ourselves in all these matters [private opioid plaintiff lawsuits]."
• "We are cooperating with this investigation [DOJ Civil Investigative Demand]."
• "We promptly took action on these products [plastic syringes] and submitted a timely and comprehensive response to the warning letter describing our investigation and corrective actions, and we continue to cooperate with the FDA on this matter."

Industry Context

Cardinal Health operates as a global healthcare services and products company, providing customized solutions across the healthcare continuum, from hospitals and pharmacies to physician offices and home care. The company is actively expanding its presence in specialty pharmaceutical products and managed services organizations (MSOs), reflecting a broader industry trend towards integrated care coordination and value-based models. The increased demand for GLP-1 pharmaceuticals highlights a significant market shift, while ongoing regulatory scrutiny, particularly concerning opioid distribution and data privacy, remains a critical industry challenge. Consolidation within the U.S. healthcare industry continues to reshape competitive dynamics, influencing customer and supplier relationships.

Comparison to Industry Standards

• The filing mentions key competitors in the pharmaceutical distribution segment, including McKesson Corporation and Cencora, Inc., and in the medical products distribution segment, such as Medline Industries, Inc. and Owens & Minor, Inc. However, no specific financial or operational benchmarks are provided for direct comparison of results against these companies within the filing.
• The company's strategic focus on MSO platforms (e.g., GI Alliance, ION, Urology America) aligns with a growing trend in the healthcare industry to enhance efficiency and profitability for independent physician practices, though specific comparable projects or results from competitors in this niche are not detailed.
• The performance graph compares Cardinal Health's cumulative total return against the S&P 500 Index and the S&P 500 Healthcare Index, showing Cardinal Health significantly outperforming both indices over the five-year period ending June 30, 2025 (367.25 vs. 215.89 for S&P 500 and 146.42 for S&P 500 Healthcare).

Corporate Governance

Legal Proceedings

• Accrued $4.9 billion for opioid-related matters as of June 30, 2025, having made payments totaling $798 million in fiscal 2025, with the majority of remaining payments expected through 2038.
• Ongoing legal proceedings with insurers regarding obligations to reimburse for defense and indemnity costs related to opioid lawsuits, with $25 million in insurance recoveries received in fiscal 2025.
• Received a Civil Investigative Demand (CID) from the Department of Justice in November 2023, focusing on potential Anti-Kickback Statute and False Claims Act violations related to a 2022 acquisition of a rheumatology MSO and GPO, with the company cooperating with the investigation.
• Accrued $56 million for losses and legal defense costs related to Cordis IVC filter product liability lawsuits, including $49 million in a qualified settlement fund, with ongoing defense against remaining claims.
• Motion to dismiss granted with prejudice in February 2025 for the generic pharmaceutical pricing antitrust civil class action lawsuit filed by indirect purchasers.
• Recognized income of $171 million for net recoveries in class action antitrust lawsuits in which the company was a class member or plaintiff during fiscal 2025.
• Reached a settlement in fiscal 2025 regarding the New York Opioid Stewardship Act, which will result in a refund of the portion paid for calendar year 2017, following a New York Appellate Division ruling that the 2017 assessment was unconstitutionally retroactive.

Related Party Transactions

• CVS Health accounted for 30% of consolidated revenue and 26% of gross trade receivables in fiscal 2025.
• The Red Oak Sourcing, LLC venture with CVS Health, which negotiates generic pharmaceutical supply contracts, requires quarterly payments to CVS Health and extends through June 2029.

Stakeholder Impact

• **Shareholders**: Benefited from increased dividends and share repurchases, and strong non-GAAP earnings growth, indicating a commitment to shareholder returns and value creation.
• **Employees**: Subject to human capital management strategies focused on attraction, retention, and development, with competitive compensation and benefits. However, restructuring and severance costs were incurred.
• **Customers**: Impacted by the expiration of the OptumRx contracts but also by the expansion of services through new MSO platforms and at-Home Solutions, aiming to enhance efficiency and provide customized solutions.
• **Suppliers**: The company's reliance on numerous suppliers and potential impacts from tariffs and supply chain constraints could affect supplier relationships and costs.
• **Creditors**: The company increased its long-term debt to fund acquisitions but remains in compliance with financial covenants, indicating a managed approach to leverage.

Next Steps

• Complete the acquisition of Solaris Health, a urology MSO, for approximately $1.9 billion in cash, subject to customary closing conditions and regulatory approvals.
• Issue common units in GIA to certain physicians and management in connection with the Solaris Health acquisition, estimated at $500 million grant date fair value.
• Integrate Solaris Health into The Specialty Alliance, the multi-specialty MSO platform.
• Fund the Solaris Health transaction with a combination of cash on hand and new debt financing.
• Continue to make annual payments under the National Opioid Settlement Agreement (NOSA) through 2038, with a $366 million payment made in July 2025.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements and reflect any impact in the period of enactment.
• Expected capital expenditures of approximately $600 million in fiscal 2026 for manufacturing and distribution infrastructure projects and technology investments.
• Anticipate combining at-Home Solutions and ADS as a single reporting unit in the future as businesses are integrated.

Key Dates

Recommendation

Cardinal Health's fiscal 2025 results, despite a revenue decline primarily due to an expected contract expiration, demonstrate robust underlying profitability and strategic agility. The significant increases in GAAP and non-GAAP operating earnings and EPS, coupled with substantial investments in high-growth MSO platforms and at-Home Solutions, indicate a successful pivot towards higher-margin businesses. The company's commitment to returning capital to shareholders through increased dividends and share repurchases further enhances its attractiveness. While ongoing litigation and regulatory risks persist, the company appears to be managing these challenges effectively. The strategic acquisitions position Cardinal Health for future growth and market leadership in evolving healthcare segments, making it a compelling 'buy' for long-term investors.

Keywords

Healthcare Services, Pharmaceutical Distribution, Medical Products, SEC Filing, 10-K, Earnings Report, Acquisitions, MSO Platforms, Opioid Litigation, Supply Chain, Risk Management, Corporate Governance, Financial Performance, CAH